Share articleAs U.S. lawmakers debate issues around health care for transgender youth, it’s been difficult to determine the ...
New research has shown that fewer than one in 1,000 US adolescents with commercial insurance receives gender-affirming ...
Among privately insured U.S. adolescents who identified as transgender and gender-diverse (TGD), receipt of puberty blockers ...
The study, published in JAMA Pediatrics on Monday, looked at private insurance claims representing over 5 million patients in ...
A new study found less than .1% of transgender and gender-diverse teens are prescribed puberty blockers or gender-affirming hormones.
From 2018 through 2022, only 926 adolescents with a gender-related diagnosis received puberty blockers and 1,927 received ...
A new analysis of private insurance claims data finds less than 0.1% of youth accessed puberty blockers or hormones for ...